ReviewTherapeutic advances in infectious disease
Multidrug-resistant tuberculosis infection and disease in children: a review of new and repurposed drugs.
Review in Therapeutic advances in infectious disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Impact of health education intervention on the knowledge and management practices of tuberculosis among patent medicine vendors in rural local government areas in Enugu, Nigeria.BMC public health · 2025Article
- Experiences of children and their caregivers affected by multidrug-resistant tuberculosis in Cape Town, South Africa.PloS one · 2025Article
- Discovery of anti-Mycobacterium tuberculosis desertomycins from Streptomyces flavofungini TRM90047 based on genome mining and HSQC-TOCSY.Scientific reports · 2024Article
- Pediatric Drug-Resistant Tuberculosis: The Current and Future Prospects for Management and Prevention.Pathogens (Basel, Switzerland) · 2023Review
- Multidrug-Resistant TB (MDR-TB) and Extensively Drug-Resistant TB (XDR-TB) Among Children: Where We Stand Now.Cureus · 2023Review
- Bedaquiline (BDQ) resistance in an adolescent with multidrug-resistant tuberculosis (MDR-TB): An alarm for pediatricians.IDCases · 2023Article
- Carborane clusters increase the potency of bis-substituted cyclam derivatives againstRSC medicinal chemistry · 2022Article
- Screening of Microbial Fermentation Products for Anti-Animals : an open access journal from MDPI · 2022Article
- Pediatric Tuberculosis Management: A Global Challenge or Breakthrough?Children (Basel, Switzerland) · 2022Review
- XDR-TB Transmitted from Mother to 10-Month-Old Infant: Diagnostic and Therapeutic Problems.Diagnostics (Basel, Switzerland) · 2022Article
- MDR Tuberculosis Treatment.Medicina (Kaunas, Lithuania) · 2022Review
- Is a high dose sufficient to achieve high isoniazid exposure in children affected by multidrug-resistant TB?The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2021Article
- Treatment Outcomes Among Pediatric Patients With Highly Drug-Resistant Tuberculosis: The Role of New and Repurposed Second-Line Tuberculosis Drugs.Journal of the Pediatric Infectious Diseases Society · 2021Article
- Recent Progress and Challenges for Drug-Resistant Tuberculosis Treatment.Pharmaceutics · 2021Review
- The Prospect of Repurposing Immunomodulatory Drugs for Adjunctive Chemotherapy against Tuberculosis: A Critical Review.Antibiotics (Basel, Switzerland) · 2021Review
- Two cases of pre-extensively drug resistant tuberculosis in children in Indonesia.Respiratory medicine case reports · 2021Article
- Screening of Compounds for Anti-tuberculosis Activity, andFrontiers in microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The World Health Organization estimates that 10 million new cases of tuberculosis (TB) occurred worldwide in 2017, of which 600,000 were rifampicin or multidrug-resistant (RR/MDR) TB. Modelling estimates suggest that 32,000 new cases of MDR-TB occur in children annually, but only a fraction of these are correctly diagnosed and treated. Accurately diagnosing TB in children, who usually have paucibacillary disease, and implementing effective TB prevention and treatment programmes in resource-limited settings remain major challenges. In light of the underappreciated RR/MDR-TB burden in children, and the lack of paediatric data on newer drugs for TB prevention and treatment, we present an overview of new and repurposed TB drugs, describing the available evidence for safety and efficacy in children to assist clinical care and decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.